Cargando…

Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease

Sickle cell disease (SCD) is one of the most common inherited blood disorders. Deoxygenated hemoglobin S (HbS) polymerizes and causes anemia and various end organ effects. Voxelotor acts by increasing HbS oxygen affinity, decreasing anemia and hemolysis. Voxelotor is approved for use in individuals...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barriteau, Christina M, Badawy, Sherif M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719266/ https://www.ncbi.nlm.nih.gov/pubmed/36471678 http://dx.doi.org/10.2147/JBM.S362222

Ejemplares similares

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022)

Voxelotor: A Ray of Hope for Sickle Disease
por: AlDallal, Salma M
Publicado: (2020)

Patient perception of voxelotor treatment benefit in sickle cell disease
por: Idowu, Modupe, et al.
Publicado: (2022)

Modeling the public health impact of voxelotor in the management of sickle cell disease in France
por: Galacteros, Frédéric, et al.
Publicado: (2023)

Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe
por: Ferlis, Mica, et al.
Publicado: (2022)

The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease
por: Minniti, Caterina P., et al.
Publicado: (2021)

Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
por: Yenamandra, Avani, et al.
Publicado: (2020)

Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor
por: Glaros, Alexander K., et al.
Publicado: (2021)

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease
por: Telfer, Paul, et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease
por: Hutchaleelaha, Athiwat, et al.
Publicado: (2019)

P1450: VOXELOTOR TREATMENT LEADS TO IMPROVED VIABILITY OF SICKLE ERYTHROCYTES
por: Konté, Kadère, et al.
Publicado: (2023)

Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma
por: Savic, Radojka M., et al.
Publicado: (2022)

P1432: PATTERNS OF VOXELOTOR USE IN A MULTICENTER, REAL-WORLD STUDY OF PATIENTS WITH SICKLE CELL DISEASE
por: Andemariam, Biree, et al.
Publicado: (2023)

5559749 A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
por: Andemariam, B., et al.
Publicado: (2023)

Voxelotor versus other therapeutic options for sickle cell disease: Are we still lagging behind in treating the disease?
por: Tayyaba Rehan, Syeda, et al.
Publicado: (2022)

Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview Study
por: Brown, Clark, et al.
Publicado: (2023)

P1485: A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
por: Andemariam, B., et al.
Publicado: (2022)

Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease
por: Alshurafa, Awni, et al.
Publicado: (2022)

5610417 IN-VITRO REAL-TIME OBSERVATION OF MODERATE SICKLING KINETICS IN SICKLE ERYTHROCYTES TREATED BY VOXELOTOR UNDER MONOTONIC AND CYCLIC HYPOXIA
por: Qiang, Y.Q., et al.
Publicado: (2023)

S279: EFFECT OF VOXELOTOR ON CEREBRAL PERFUSION AND CEREBRAL OXYGEN METABOLISM IN ADULT PATIENTS WITH SICKLE CELL DISEASE; THE COVERAGE STUDY
por: Konté, Kadère, et al.
Publicado: (2023)

Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action
por: Green, Michelle L., et al.
Publicado: (2022)

Fetal hemoglobin level and nutritional status in patients with sickle cell disease
por: Badawy, Sherif M.
Publicado: (2016)

Voxelotor Treatment Providing Transfusion Independence for Patient With Combined Sickle Cell Disease and Lipopolysaccharide-Responsive and Beige-Like Anchor (LRBA) Deficiency
por: Larkin, Kelsey M, et al.
Publicado: (2023)

PB2516: ACTIGRAPHY IMPROVEMENT WITH VOXELOTOR (ACTIVE) STUDY: IMPACT OF VOXELOTOR ON PHYSICAL ACTIVITY, FATIGUE, AND SLEEP QUALITY
por: Shah, Nirmish, et al.
Publicado: (2023)

More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
por: Langley, Paul C
Publicado: (2020)

More to voxelotor than meets the eye?
por: Bovino, Robert C., et al.
Publicado: (2022)

S118: LONG-TERM SAFETY AND EFFICACY OF VOXELOTOR FOR PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM AN OPEN-LABEL EXTENSION OF THE PHASE 3 HOPE TRIAL
por: Achebe, M, et al.
Publicado: (2022)

Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review
por: Dick, Maurice H, et al.
Publicado: (2022)

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
por: Preston, Richard A., et al.
Publicado: (2020)

Voxelotor Modulates the Analgesic Effect of Certain Opioids
por: Ballas, Samir K.
Publicado: (2021)

Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review
por: Yang, Mira, et al.
Publicado: (2022)

P-013: VOXELOTOR REDUCES SICKLE RED BLOOD CELL-MEDIATED HYPOXIC MICROVASCULAR OCCLUSION AS MEASURED BY OCCLUSIONCHIP IN VITRO MICROFLUIDIC ASSAY
por: Z., SEKYONDA, et al.
Publicado: (2022)

5579775 OVERVIEW OF THE VOXELOTOR POST-APPROVAL CLINICAL RESEARCH PROGRAM
por: Minniti, C., et al.
Publicado: (2023)

Patient-Centered eHealth Interventions for Children, Adolescents, and Adults With Sickle Cell Disease: Systematic Review
por: Badawy, Sherif M, et al.
Publicado: (2018)

Association between Participants' Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease
por: Badawy, Sherif M., et al.
Publicado: (2018)

5613294 BASELINE PATIENT CHARACTERISTICS FROM A UK EARLY ACCESS TO MEDICINES SCHEME (EAMS) WITH VOXELOTOR, A HBS POLYMERIZATION INHIBITOR, FOR THE TREATMENT OF HEMOLYTIC ANEMIA DUE TO SICKLE CELL DISEASE
por: Eleftheriou, P., et al.
Publicado: (2023)

Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents
por: Reddy, Paavani S., et al.
Publicado: (2022)

P1445: THE IMPACT OF ILLNESS PERCEPTION AND STIGMA ON PATIENT-REPORTED OUTCOMES IN SICKLE CELL DISEASE
por: Winkler, Savannah, et al.
Publicado: (2023)

P1442: PRACTICE-BASED EVIDENCE: LONG-TERM SAFETY COHORT OF DEFERIPRONE IN PATIENTS WITH SICKLE CELL DISEASE FROM THE US REGISTRY
por: Badawy, Sherif, et al.
Publicado: (2023)

P1434: THE RELATIONSHIP BETWEEN MEDICATION ADHERENCE, BARRIERS TO MEDICATION ADHERENCE, AND QUALITY OF LIFE IN SICKLE CELL DISEASE
por: King, Kathryn, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cbmve9hm7lgluqpc9o1sp80m4b